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Numerous neurological disorders are caused by a dysfunction of the GABAergic system that impairs or either stimulates its
inhibitory action over its neuronal targets. Pharmacological drugs have generally been proved very eﬀective in restoring its
normal function, but their lack of any sort of spatial or cell type specificity has created some limitations in their use. In the
last decades, cell-based therapies using GABAergic neuronal grafts have emerged as a promising treatment, since they may restore
the lost equilibrium by cellular replacement of the missing/altered inhibitory neurons or modulating the hyperactive excitatory
system. In particular, the discovery that embryonic ganglionic eminence-derived GABAergic precursors are able to disperse and
integrate in large areas of the host tissue after grafting has provided a strong rationale for exploiting their use for the treatment of
diseased brains. GABAergic neuronal transplantation not only is eﬃcacious to restore normal GABAergic activities but can also
trigger or sustain high neuronal plasticity by promoting the general reorganization of local neuronal circuits adding new synaptic
connections. These results cast new light on dynamics and plasticity of adult neuronal assemblies and their associated functions
disclosing new therapeutic opportunities for the near future.
1. Introduction
γ-Aminobutyric acid (GABA) is the major inhibitory neuro-
transmitter in the central nervous system (CNS), playing a
key role in the balance between inhibitory and excitatory cir-
cuits [1, 2]. Therefore, it is not surprising that dysfunctions
in the GABAergic system lead to pathological conditions
including hypokinetic diseases such as Parkinson’s disease
(PD), and hyperkinetic diseases, such as Huntington’s disease
(HD), when disruption of the GABAergic system occurs in
the basal ganglia [3–5]. Epilepsy, a pathology characterized
by uncontrolled hyperactivity, is also tightly linked to deficits
in GABA levels, as well as alterations in its synthesis,
secretion, and reuptake, or reductions in the number of
GABAergic interneurons [6–8].
Almost 25 years ago, it was already postulated that
controlling GABA delivery to specific brain areas should
benefit each of these diseases [9, 10]. Cell transplantation
is a powerful tool to introduce a new source of GABA and
may allow reconstitution of neural circuits in the diseased
brain [11, 12]. To be successful, grafted cells should possess
the ability to disperse through aﬀected areas and diﬀerentiate
into fully mature neurons expressing appropriate neuro-
transmitters, in this case GABA. Ideally, these cells should
also functionally integrate and modulate circuitry activity in
the damaged host brain; for instance, aﬀecting its plasticity.
Since the pioneer works from Lindvall and Bjo¨rklund [9]
and Isacson et al. [10], several transplantation assays with
diﬀerent GABA-producing cell types have been performed
with disparate success in animal models of diseases. Many
cell types were partially successful in reverting some of
the pathological anomalies observed in the grafted models.
However, some of them presented important drawbacks,
such as their poor tissue distribution, transient eﬀect, maybe
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due to decreased GABA release over time [13–15], or in the
case of ES cells, the lack of safety due to potential generation
of teratocarcinomas [16, 17].
In the last decade, a better comprehension of how and
where the cortical and hippocampal interneurons originate
has led to use their neuronal precursors in transplantation
[18, 19]. We currently know that most of the GABAergic
interneurons in the cortex and hippocampus are mainly
generated in two regions of the subcortical telencephalon,
known as the caudal and medial ganglionic eminence
(CGE and MGE), from where they migrate tangentially to
their final destination in the cerebral cortex [19–22]. In
the last years, several groups have reported regenerative
works using these MGE-derived GABAergic precursors, with
striking results [23–28]. At present, they represent the
most promising cell-based therapeutic alternative for GABA-
related diseases.
In this paper, we will summarize the main regenerative
approaches using GABAergic grafts for the treatment of
epilepsy and neurodegenerative disorders. These include
the use of diﬀerent sources of GABAergic precursors, with
a special emphasis in the MGE-derived cells, and their
transplant in several model organisms of disease. In addition,
we will also describe the implications of the GABAergic grafts
on themodulation of synaptic activity and circuitry plasticity
of the host.
2. GABAergic Cell Therapy for Epilepsy
Epileptic seizures reflect a hyperexcitation in the brain,
which is attributed to an imbalance between inhibitory
and excitatory networks [6]. Given the close relationship
between GABA and epilepsy [6, 8], antiepileptic drugs
(AED) targeting the GABAergic system are traditionally
the preferred treatment, presenting an acceptable eﬃcacy
[29, 30]. However, up to a third of patients continue to
experience seizures on maximal tolerated drug therapy [31,
32]. Refractory epilepsy remains a large clinical problem,
since surgical resection is only appropriate for a minority
of patients [33, 34]. In the last decades, cell-based therapies
using GABAergic grafts have emerged as an alternative treat-
ment for epilepsy, since they may restore the lost equilibrium
by cellular replacement of the missing/altered inhibitory
neurons or modulating the hyperactive excitatory system
[35–37]. The therapeutic strategies are multiple: general
secretion of GABA, by the grafted cells to increase the seizure
threshold, or specifically located in the focus of epilepsy
and/or the areas responsible for seizure transmission to block
it; direct replacement of malfunctioning or lost inhibitory
interneurons; interaction of the transplanted GABAergic
cells with activating system to modulate its plasticity, and
levels of activity; finally, rewiring of aberrant excitatory
fibers, such as mossy fiber in temporal lobe epilepsy (TLE),
towards inhibitory GABAergic cells.
According to these strategies, several GABAergic cell
types, with diﬀerent origins and characteristics, have been
assayed in animal models of epilepsy to evaluate their
therapeutic potential. In the following sections, we describe
in detail the most representative cell types and assays.
2.1. GABA-Producing Cells. A first therapeutic approach for
epilepsy includes transplantation of fetal precursors from
diﬀerent brain regions, and cells genetically modified to
produce and secrete GABA were transplanted into the hip-
pocampus or in regions implicated in seizure generalization
[9, 13–15, 38–41]. More than 20 years ago, Stevens et al.
transplanted embryonic cerebellar and cortical tissue, rich
in GABA or norepinephrine neurons, in the amygdala-
kindled rat model of epilepsy [41]. Transplantation into the
deep prepiriform area transiently raised seizure thresholds,
showing for the first time that cell transplantation could
be valuable for epilepsy treatment. Previously, Isacson et al.
had already shown that transplantation of GABAergic cells
from striatal primordia significantly ameliorates the lesion-
induced locomotor hyperactivity in the ibotenic acid rat
model of HD [10]. These seminal works strongly suggested
that intracerebral grafting of inhibitory neurons may be an
adequate strategy for seizure suppression [9]. Following this
strategy, several groups isolated cells from the late striatal
primordial (E14-15 in rats), to transplant them in regions
thought to be critically involved in seizure propagation,
such as the substantia nigra, as an eﬀective means of
permanently blocking seizure generalization in diﬀerent
models of epilepsy, mainly kindled rats [13, 14, 38–40].
All the kindling studies reported significant increase in
afterdischarge thresholds and marked reduction in seizure
severity compared with pretransplantation values [13, 17,
42]. In drug-induced models of epilepsy, these cells also
suppressed the development of motor-limbic seizures and
reduced the mortality rate [38–40]. However, the seizure-
suppressing eﬀect of GABAergic grafts was transient, likely
due to progressive reductions in GABA levels. For this reason,
it was attempted the development of immortalized glial
and neuronal cell lines genetically engineered to produce
GABA [37–39, 43, 44]. The ability to generate self-renewing
clonal populations of transplantable GABA-producing cells
provides an unlimited cell source and a good level of
control on GABA production. GABA-producing cell lines
demonstrated the ability to retard the development of
seizures and block the expression of established seizures in
kindling, kainic acid, and pilocarpine models of epilepsy
[37–39, 43, 44]. However, these cell lines presented serious
limitations that diminish their clinical potential [37]. The use
of the SV40 large T oncogene for their immortalization raises
concerns about tumorigenicity [38, 39]. In addition, in the
host brain, a strong tissue reaction was reported including
graft rejection, massive infiltration of inflammatory immune
cells, and gliosis. Besides the concerns of tumorigenicity
and immunogenicity, a major problem was the inability
to sustain long-term eﬀects due to the lack of survival or
integration of the graft-derived cells [37]. To date, there
is no report of engineered neuronal cells becoming fully
diﬀerentiated and integrated into the seizure circuit of the
host. This lack of integration may limit access to trophic
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factors and thus reduce the survival potential of these cells,
and as a consequence, their mediated eﬀects are transient.
2.2. Neuronal and Embryonic Stem Cells. The establishment
of techniques that allow the isolation and culture of embry-
onic stem cells (ESCs), and neuronal stem cells (NSCs)
from fetal and adult brain tissue, provided new sources
of GABAergic cells for treating epilepsy to the scientific
community [45, 46]. ESCs are isolated from the inner cell
mass of the developing blastocyst and retain the ability
to generate every cell type present in the body, including
neurons [47, 48]. NSCs show a more restricted ability to
generate only those cell types that constitute the nervous
system; neurons, astrocytes, and oligodendrocytes [49].
NSCs can be expanded in culture using mitogens, mainly
bFGF and EGF, which keep them in an undiﬀerentiated
state, forming floating cell aggregates, named neurospheres
[50, 51]. Both cell types, ESCs and NSCs, are very promising
in terms of providing an infinite supply of donor cells
for neuropathological condition treatments. An additional
advantage is the possibility to direct their diﬀerentiation
toward specific cell types, in this case GABAergic neurons.
In fact, default diﬀerentiation pathway for many SC lines in
culture seems to be the GABAergic lineage [52, 53].
Despite these interesting properties, few studies report
on the use of ESC and NSC in animal models of epilepsy
[45, 46]. Ru¨schenschmidt et al. [54] reported that ESC-
derived neuronal precursors (ESNPs) transplanted into the
hippocampi of both control and pilocarpine-treated rats
were able to generate action potentials and expressed voltage-
gated Na+ and K+ currents, as well as hyperpolarization-
activated currents. Anyway, electrophysiological activity and
action potentials were lower than those in host neurons,
typical of immature cells and suggesting an incomplete
maturation process. Indeed, the grafted cells formed big
clusters, and there was no evidence of cell type-specific
diﬀerentiation one month after the transplant. In addition,
no obvious diﬀerence was found between the functional
properties of the transplanted cells in sham control and in
pilocarpine-treated rats, and no improvement was described
in the symptoms or electrophysiological activity of the
epileptic rats after the transplants.
In contrast, Carpentino et al. [55] reported that grafted
ESNP into the normal and kainic acid-treated mice par-
tially migrated and diﬀerentiated towards neuroblasts and
dentate granule neurons, or oligodendrocytes and astrocytes,
depending on the brain area where they were finally located.
However, some cells grafted in mice not subjected to seizures
displayed a marked tendency to form tumors, and this
eﬀect was more pronounced in the dentate gyrus than in
the fimbria. This suggested that seizures induce molecular
changes that promote region-specific neural diﬀerentiation
and suppress tumor formation. Finally, eﬀects on the
epileptic condition of the mice after ESNP transplantation
were not reported, as well.
More recently, Shindo et al. [56] optimized a method
to induce diﬀerentiation of GABAergic neurons from ESNP,
and transplanted them into kindled epileptic mice to analyze
a possible morphological and functional recovery. Two weeks
after transplant, they observed a partial recovery of seizures.
This was likely due toGABA production of transplanted cells,
since histological analysis showed a high percentage of cells
expressing GAD67. However, the morphology and cluster
formation of the grafted cells suggest a lack of integration
in the host circuitry.
From these reports, it is evident that the use of ESC in
epilepsy treatment needs to be improved. Safer conditions
to avoid tumorigenicity are necessary, and percentage and
quality of diﬀerentiation toward GABAergic neurons should
be increased. Improving the diﬀerentiation protocols from
ESC and generating cell lines that are strongly committed
to specific neural lineages in culture prior to grafting might
be helpful. Several groups are working with this idea and
have reported advances in the generation of GABAergic
interneurons from ESC with high eﬃciency in vitro [57] and
a good degree of functionality in vivo [58].
NSCs partially overcome some of the problems presented
by ESC. They can be isolated from fetal or adult brain
regions already committed in the generation of certain types
of neurons; moreover, they prevent ethical issues and do
not form tumors; and they could potentially be harvested in
culture for prolonged periods, as neurospheres, to be used
as a source of donor tissue for grafting [49–51]. Shetty et
al. have isolated and cultured NSC from two fetal regions of
the rat and grafted them in epileptic models. In a succession
of reports using E19 hippocampal grafts or cultured NSC
from this region [59–65], they reported the ability of this
precursors to give rise to both hippocampal pyramidal-
like neurons and interneurons in the host brain. However,
barely more than 50% of transplanted neurospheres became
diﬀerentiated cells, showing mainly an astrocyte phenotype
and only in a small proportion a neuronal one. Integration
of the transplanted cells was also poor; they form big clusters
interfering with the normal hippocampal morphology. How-
ever, grafts located in or near the degenerated CA3 cell layer
established commissural projections with the contralateral
hippocampus. In addition, they revealed the capability of
these grafts to restore disrupted hippocampal mossy fiber
circuitry by attracting host mossy fibers suﬃcient to suppress
the development of aberrant circuitry in hippocampus. The
graft-induced long-term suppression of aberrant sprouting
may provide a new avenue for amelioration of hyperex-
citability [62].
Similarly to the previous reports, the Shetty’s group
transplanted striatal NSCs in the hippocampus of adult
rats after status epilepticus induced by kainic acid [66].
The cells, pretreated with fibroblast growth factor-2 and
caspase inhibitors, presented a good survival rate but limited
ability to migrate, remaining close to the injection site.
Nonetheless, a small percentage of these cells diﬀerentiated
into GABAergic neurons and were able to reduce the seizure
frequency in the kainic acid model of TLE.
Human NSC have been also tested in the pilocarpine-
induced rat model of TLE [67]. They diﬀerentiated into
cells that were positive for GABAergic (26%), glutamatergic
(2%), or astrocytic (21%) markers. Grafted cells reduced
the amplitude of extracellular field excitatory postsynaptic
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potentials in the hippocampal CA1, decreased the percentage
of pilocarpine rats that developed spontaneous seizures, and
declined both seizure frequency and severity.
2.3. MGE-Derived Neuronal Precursors. As mentioned in
the introduction, in the last decade, the origin of cor-
tical and hippocampal GABAergic interneurons has been
elucidated [19–22]. Located in a restricted region of the
ventral telencephalon known as the MGE and CGE, these
precursors migrate long distances to cover the neocortex
and hippocampal primordial where they complete their
diﬀerentiation. In theory, these precursors should be good
candidates for treating GABA-related diseases, since they are
already committed to interneurons and migrate naturally
long distance covering the brain parenchyma. They should
overcome the diﬃculties presented by other sources of cells
and achieve higher levels of inhibition or modulate the
excitatory activity in the host. To verify this possibility, our
group grafted fresh isolated, with no other manipulation,
MGE-derived precursors into the neonatal normal brain
[18]. MGE-derived cells gave rise to neurons that migrated,
embracing wide areas of the cortical plate, striatum, and
the hippocampus. More than 70% of the grafted cells
diﬀerentiated into fully mature GABAergic interneurons,
demonstrated by the expression of molecular markers such
as calcium binding proteins. More importantly, electro-
physiological analysis demonstrated these cells were able to
integrate into the local circuits and make functional synapses
with existing neurons, influencing the level of GABA-
mediated synaptic inhibition. This was the first time that full
mature electrophysiological activity and modulation of the
host activity by GABAergic grafts was demonstrated. These
observations strongly suggested the complete maturation of
the grafted cells and its suitability for cell-based antiepileptic
therapies.
In the following years, several groups tested these MGE-
derived cells in diﬀerent animal models of epilepsy. As proof
of principle for a cell replacement therapy after lost or
reductions in GABAergic neurons, our group grafted MGE-
derived cells into a mouse model with a disinhibited brain
environment caused by specific ablation of interneurons
[28]. This was achieved by intrahippocampal microinjection
of the neurotoxic Saporin conjugated with an analog of sub-
stance P (SSP-Sap), that selectively targets and eliminates the
GABAergic interneurons expressing the substance P receptor,
neurokinin-1 (NK-1) [68]. This experimental approach
helped to address whether MGE-derived interneurons can
integrate under neuropathological conditions and not only
increase but also restore deficits in the inhibitory synaptic
function as consequence of reductions in the number of
GABAergic neurons. The specific GABAergic ablation leads
to reductions in GABA-mediated synaptic inhibition, hyper-
excitability, and increased susceptibility to pentylenetetrazol-
induced seizures (PTZ), similarly to other models with
reductions in interneurons [68–70]. MGE-derived cells in
SSP-Sap-treated mice repopulate the hippocampal ablated
zone with cells expressing molecular markers of mature
interneurons. Similar to transplants in normal neonatal
brain [18], the grafted MGE-derived cells migrated long
distance covering the whole ablation area and acquired a
fully mature morphology two months after transplantation
with good survival rates (∼25%). Immunohistochemical
analysis revealed that more than 60% of graft-derived cells
expressed GABA and specific molecular markers for mature
interneuron subpopulations. Interestingly, electrophysio-
logical analysis showed a restoration of the postsynaptic
inhibitory current kinetics on CA1 pyramidal cells of ablated
hippocampus after transplant, and more importantly, this
was associated with reduction in seizure severity and decrease
in postseizure mortality induced by PTZ [28] consistent
with an enhancement of GABAergic inhibition after cell
transplantation. In addition, these eﬀects were stable over
time. We performed a followup to 6 months after the
transplant with similar results. This is logical, since we have
verified MGE-derived cell survival more than 1 year after
the transplant and, importantly, tumor formation was never
detected.
MGE-derived cells are able not only to replace a loss
of GABAergic neurons and reduce the mortality to PTZ-
induced seizures, but also they show an intrinsic antiepilep-
togenic activity. Baraban et al. [23] grafted MGE-derived
cells into neonatal Kv1.1 mutant mice, characterized by the
lack of voltage-activated K+ channel, Kv1.1. These mice
exhibit a high frequency of behavioural and electrographic
seizures few weeks after birth. GABA-mediated synaptic
and extrasynaptic inhibition onto host brain pyramidal
neurons was significantly increased after bilateral trans-
plant, and significant reductions in the total number,
duration, and frequency of spontaneous electrographic
seizures were observed. These findings suggest that MGE-
derived interneurons could prevent and ameliorate abnormal
excitability in infants. This is an interesting possibility,
since MGE grafts may block generalization of seizures and
improve life conditions in the patients. We have confirmed
the anticonvulsant ability of these cells by maximum elec-
troconvulsive shock (MES) assay after grafting in neonatal
mice [24]. MES has remained one of the gold standards for
AED screening [71]. The test evokes a single seizure applying
a high-intensity current. Two months after transplantation
in postnatal day 3 mice, MGE-grafted cells were able to
protect against clonic seizures induced by MES, and a 5-
fold reduction in the mortality rate was observed. This data
strongly suggests that MGE grafts block the generalization
of the seizures and allow a better control of the transition
between tonic and clonic seizures. If we consider the MGE-
grafts as a new AED, they perform better in MES assay than
many AEDs already commercially available in the clinic.
However, before thinking of a clinical application of this
cell type, some technical problems should be eliminated
for instance, the limiting number of cells available for
transplantation. One possibility is the amplification ofMGE-
derived cells in culture. MGE cells, cultured as neurospheres,
have also been tested in the kainic acid model of TLE [27].
However, the interaction of MGE precursors with mitogens
in culture seems to modify importantly their behaviour
and neuronal commitment. MGE neurospheres gave rise
mainly to astrocytes and only in a small proportion to
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GABAergic cells after transplantation. Nonetheless, these
cells grafted into the hippocampi of adult rats restrained
spontaneous recurrent motor seizures, with no improvement
of the cognitive function. Authors suggested that expression
of GDNF by more than 50% of the grafted cells may underlie
the therapeutic eﬀect of MGE-NSC grafts, given the role in
seizure suppression of this neurotrophic factor [72].
Taken together all these works, we have a scenario
where MGE-derived cells are the most promising source of
GABAergic neurons for cell-based therapies. However, before
clinical application, we should continue studying the possible
implication of the interaction of new grafted cells with those
from the host; their modulation of synaptic activity, maybe
by modifying neuronal plasticity; the possible consequences
on behaviour. We will review these implications in the
following section. However, we should have in mind that
epilepsy etiology is multiple, and in consequence not all
of the epilepsies should response equally to MGE-derived
interneuron grafts. In addition, we should be cautious.
Certain types of GABAergic interneurons together with
aberrantly behaving excitatory pyramidal neurons in the
subicular region of the hippocampus can precipitate epileptic
seizures instead to stop them [73]. In keeping with this idea,
it has been also reported a role of GABA-mediated signaling
in ictogenesis, contributing to epileptiform synchronization
that lead to the generation of electrographic ictal events in
the cingulated cortex and limbic areas of the brain [74, 75].
Therefore, grafting of certain subclass of GABA-producing
cells in a wrong location in some epilepsy types may lead to
seizure exacerbation.
Before clinical application, we should continue exploring
the eﬀects of the grafts on several animal models of epilepsy
with diﬀerent etiologies; study the possible implication
of the interaction of new grafted cells with those from
the host; their modulation of synaptic activity, maybe by
modifying neuronal plasticity and the possible consequences
on behaviour. We will review these implications in the
following sections.
3. GABAergic Grafts for Parkinson’s Disease
(PD) and Stroke
PD is triggered by the loss of mesencephalic dopaminergic
neurons localized in the substantia nigra pars compacta
(SNpc). This cellular loss eliminates dopaminergic pro-
jections to the striatum and their supply of dopamine
which modulates striatal-dependent extrapyramidal motor
behaviour. Therefore, PD patients experience motor dys-
functions including tremor, rigidity, bradykinesia, and pos-
tural instability. Alleviation of motor symptoms is obtained
by the administration of the dopamine precursor L-DOPA;
however, its prolonged use over years induces the develop-
ment of severe side eﬀects known as dyskinesia (abnormal
involuntary movements) that only in part are mitigated by
diﬀerent regimens of pharmacological coadiuvants.
In addition, many attempts of gene and cell-based
therapies are in progress to establish treatments that can be
complementary and additive to the standard pharmacolog-
ical approach. In particular, a gene therapy approach has
been developed to deliver the glutamic acid decarboxylase
(GAD) gene, catalysing the synthesis of GABA, directly into
neurons of the subthalamic nucleus [76]. In PD, activity of
the subthalamic nucleus (STN) is increased mainly because
of reduced GABAergic input from the globus pallidus. Inter-
estingly, the focal delivery of GAD in the STN contributed
to reducing its overactivity leading to an amelioration of
the clinical neurological symptoms. Safety and tolerability
of this gene therapy protocol has been demonstrated in a
phase I trial although with a reduced number of patients and
over a limited period of time (1 year) [77]. Thus, promoting
GABAergic neuronal activity in specific nuclei can contribute
in restoring a balance in the basal ganglia neuronal outflow
controlling the extrapyramidal motor system.
In addition to these approaches, the clinical impact of
cell replacement has been evaluated in animals and humans
over the last two decades. These approaches are aimed
to reconstitute a local dopaminergic network capable of a
feedback controlled dopamine release upon delivering of
dopaminergic neurons in the aﬀected striatal compartment.
A similar procedure has been pioneered in humans using
cellular grafts of fetal nigral tissues [78–80]. This approach
led to some important symptomatic improvements, however,
often associated with the development of extremely severe
dyskinesia [81]. These side eﬀects are probably due to the
high heterogeneity of the grafted tissue containing only a
minimal fraction of dopaminergic precursors (5%) in an
overall population of diﬀerent cell types including serotoner-
gic and GABAergic neurons [82, 83]. Recently, an alternative
strategy of cell transplantation has been validated in a PD
animal model. This is based on transplanting GABAergic
precursors isolated from the embryonic MGE/CGE into the
adult striatum [84]. At first glance, this approach introducing
inhibitory neurons in a tissue already deprived of dopamine
might seem counterintuitive. However, thinking of PD as an
activity outflow unbalance among diﬀerent striatal neuronal
networks, this methodology finds a strong rationale [85].
Noteworthy, E14.5 MGE/CGE cells injected into a single
site were able to migrate throughout the striatal tissue,
but not beyond it. The extent of migration is similar to
that described for these cells upon transplantation into the
adult cortex (see above). Therefore, MGE/CGE GABAergic
neuronal precursors have a tendency to actively disperse
within diﬀerent adult brain tissues, and this represents a
strong attractive feature for an eﬃcient cell-based therapy.
However, this should not be considered of general rule, since
the same cells grafted in the subthalamic nucleus are unable
to migrate from the injection site [84]. Possibly, this is the
case since cortex and striatum, contrary to thalamic areas,
are the forebrain regions which are normally colonized by
these cells during embryogenesis and might retain some
molecular or structural cues that allow this behaviour even
in adulthood. Are these cells able subsequently to survive,
mature, and integrate in the host striatal tissue? Martı´nez-
Cerden˜o and colleagues found that despite the great major-
ity of the MGE/CGE-transplanted cells which were lost
after 1 year from transplantation, 1% of them survived
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and presented morphological and functional features of
mature interneurons of the three major subtypes, namely,
calretinin+, parvalbumin+, and somatostatin+ cells [84].
Therefore, only a minimal fraction of MGE-transplanted
cells are able to survive for long time in the striatal tissues
and this probably reflects the need for establishing stable
and functional connections with the host neuronal network
for promoting their survival. Remarkably, even though the
transplanted interneurons accounted for only about 5% of
the total endogenous GABAergic neuronal population, they
were suﬃcient to elicit a significant motor and behavioural
recovery in the 6-hydroxydopamine-lesioned rats. How
might this occur? The authors revealed the integration of
the grafted interneurons by showing the formation of de
novo synapses with the host neurons, and hence, they
suggest that it is the graft-mediated reorganization of the
basal ganglia network that fosters the functional recovery
observed [84]. In fact, the striatum is the key centre of
the extrapyramidal tract which controls thalamic eﬀerents
to the motor cortical regions. This circuitry is organized
in two main neuronal assemblies known as the direct and
the indirect pathways. The first connects striatum-internal
globus pallidus and thalamus and activates thalamic activity.
The second restrains thalamic activity and is connecting
striatum-internal and -external globus pallidus and thala-
mus. Hence, these two pathways converge to the thalamus
as their final target centre and regulate its activity by playing
reciprocal opposing functions. In PD, dopamine depletion
in the striatum produces two concomitant eﬀects. First, it
reduces the activity of the direct pathway while promoting
the indirect pathway creating an upraised inhibitory outflow
to the thalamus.
One plausible mechanism by which MGE-transplanted
cells promote a symptomatic relief in PD animals is to restore
a balance in the total output of these two pathways over the
thalamus by preferentially inhibiting the indirect pathway
[85]. Although this explanation needs more experimental
evidences, nonetheless these studies reveal how a small
transplanted population of interneurons has the capability
to modulate the plasticity of long-ranging and complex neu-
ronal circuitry and restore a functional unbalance between
related neuronal systems.
Recently, similar cell transplantations of embryonicMGE
GABAergic precursor cells have been carried out in a
mouse model of stroke [86]. Focal ischemia in cortical and
nearby striatal areas was produced by middle cerebral artery
occlusion, and embryonic MGE cells were transplanted
in multiple sites in adjoining regions. Noteworthy, MGE-
transplanted animals improved in their locomotion and
motor coordination with a significant improvement in both
tests respect to sham-injected controls [86]. Similar to
previous studies, embryonic MGE cells developed in fully
mature neurons featuring spontaneous action potentials and
connecting to host neurons. However, the amount of MGE
grafted cells that diﬀerentiated into mature neurons after
4 weeks from transplantation were only a limited fraction
accounting for 20% of the total. Surprisingly, the rest of
the cells resulted negatively for astrocyte or oligodendrocyte
markers indicating that the transplanted cells remain blocked
to a progenitor state unable to complete the diﬀerentiation
in any cell lineage [86]. This is in striking contrast with the
diﬀerentiation behavior of grafted MGE cells in the other
disease murine models previously described [82].
Nonetheless, the authors noted that theMGE cell grafting
stimulates axonal reorganization of the host tissue [86]. In
fact, the axonal sprouting and neurite reorganization in the
injured site was strongly increased after cell transplantation.
These results suggest that grafted MGE neurons might
stimulate endogenous repairing mechanisms or formation
of alternative neuronal assemblies to support the functions
of the lost tissue. To which extent exogenous MGE cells can
trigger neuronal rewiring and plasticity of the host tissue
remains to be better exemplified. To be noted, also MGE
cell graftings in PD animal models induced some changes
in the host tissue as for instance the re-expression of the
calcium-binding proteins calretinin and calbindin by host
striatal cells nearby the transplantation site [84]. The changes
might also be promoted by all sorts of trophic factors released
by the grafted GABA neuronal precursors that can stimulate
neuritogenesis or synaptic connections.
Although many questions remain unanswered, trans-
plantation of embryonic MGE GABAergic cells has resulted
surprisingly eﬀectively in promoting clinical improvements
in animal models for diﬀerent chronic or acute neurological
disorders. These results call for a better understanding of
the cellular and molecular mechanisms by which the MGE
grafts can promote this positive outcome. One of them may
be the increased delivery of GABA neurotransmitter. To
date, direct biochemical measure of GABA concentrations
after MGE-derived grafting has not been reported. However,
patch clamp analysis of spontaneous postsynaptic inhibitory
currents in projection neurons of the grafted area strongly
suggests a direct eﬀect on their frequency and amplitude,
mediated specifically by presynaptic GABA delivery from the
transplanted cells [18, 28]. One other mechanism may be
secondary to release of trophic factors by the grafted cells.
GDNF has been reported to be secreted by the astrocytes
cotransplanted with the MGE cells [27], what improve
epileptic condition. We cannot discard the delivery of some
other neurotrophic factors that stimulate endogenous repair-
ing mechanisms, or even neurogenesis, as mentioned above.
Further eﬀorts should be devoted to decipher the multiple
mechanisms implicated in the functional outcomesmediated
by GABAergic cell transplants, including modulation of
endogenous plasticity.
4. MGE GABAergic Cellular Grafts Induce
Cortical Plasticity
Cortical circuits are sensitive to experience during well-
defined intervals of early postnatal development called
critical periods [87, 88]. After the critical period, plasticity is
reduced or absent. Monocular deprivation (MD) is a classic
model of experience-dependent plasticity. In the mammalian
binocular visual cortex, neurons are activated to diﬀerent
degrees by visual stimuli presented to one eye or the other, a
property called ocular dominance (OD). If vision is normal
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for both eyes during development, the majority of visual
cortical neurons are binocular. If one eye is occluded during
development, visual cortical neurons become dominated
by the nondeprived eye. This change in OD is taken as
a sensitive index of plasticity of visual connections. OD
plasticity is particularly high during a critical period of
postnatal development and declines with age [89, 90].
Accumulating evidence supports a pivotal role for late-
developing excitation versus inhibition circuit balance in
the initiation of sensitive periods. For example, the onset
of visual cortical plasticity is delayed by genetic disruption
of GABA synthesis [91, 92]. Conversely, the application of
benzodiazepines or other treatments that accelerate GABA
circuit function triggers premature plasticity [93]. Therefore,
the onset of OD plasticity is triggered by the establishment
of a functional network of inhibitory synaptic transmission.
Southwell and colleagues asked whether transplantation of
MGE GABAergic precursors could be suﬃcient to trigger
a plasticity respond in the host cortex [94]. In mice, OD
plasticity reaches a peak in the fourth postnatal week, when
cortical inhibitory neurons are 33–35 days old. Thus, the
authors transplanted E13.5 mouse MGE GABAergic precur-
sors in perinatal or early-postnatal brains and ascertained the
induction of visual plasticity in the host brains [94]. Grafted
MGE cells diﬀerentiated into GABAergic interneurons with
a great eﬃciency and only 0.2% of them developed mor-
phology of astrocytes. Remarkably, the cellular graftings were
able to successfully trigger visual plasticity in the host [94].
However, this induction was achieved only for a short period
of time which correlated with the age of the transplanted
cells. In fact, transplantation was eﬀective when the cells were
33–35 days while soon later at 43–46 days old the same cells
failed to trigger the same eﬀect. Therefore, the cellular age of
the transplanted population strictly determines the eﬀects on
cortical plasticity.
The introduction of a supplemental amount of inhibitory
interneurons would suggest that an increased inhibitory
tone is the trigger for such neural rejuvenation. However,
this is not the case since pharmacological enhancement of
inhibition does not induce similar eﬀects [95]. The answer
is rooted probably in the nature of the synaptic contacts
established by grafted interneurons with the host neuronal
circuitry. Indeed, transplanted inhibitory neurons formweak
but numerous synaptic connections with neighbouring exci-
tatory neurons in the host brain. Thus, these new connec-
tions are believed not to simply raise the general inhibitory
tone, but rather to promote an overall reorganization of the
cortical circuitry by introducing a new set of weak inhibitory
synapses. This pattern of newly established synaptic contacts
represent an ideal biological substrate capable of enhancing
the Hebbian plasticity mechanisms during the critical period
[96].
It is noteworthy that the grafted interneurons promote
plasticity only when they reach a cellular age comparable
to that of the endogenous counterpart during the critical
period. This data strongly suggest that plasticity is suc-
cessfully initiated by a cell-autonomous program endowed
in interneuron progenitors which is minimally influenced
by the age of the host tissue. These findings open a new
scenario where cell transplantation might be eﬀective in
reprogramming neural activity up to triggering plasticity
processes. Nonetheless, a number of questions need to
be answered to understand the safety and eﬃcacy of this
procedure. For instance, (i) whether transplantations of
interneurons are able to induce visual plasticity even in the
adulthood, (ii) if the grafted animals display any neuronal
misbehaviour at later stages triggered by the action of the
transplanted cells, (iii) if plasticity is promoted by a specific
class of interneurons, and (iv) the assessment of the minimal
number of cells to be grafted for inducing brain plasticity.
Although the transplanted-induced plasticity lasts for
few days, this might be suﬃcient to trigger long-lasting
neural circuitry reorganization. On this view, this procedure
opens the exciting opportunity to induce or facilitate the
restoration of normal function in injured or degenerative
disorders. Future studies are warranted to assess the regener-
ative potential of this approach in the developing and adult-
diseased brains.
5. New Sources forMGE GABAergic Neurons
Considering the findings described above, MGE GABAer-
gic neurons exhibit properties well suited for therapeutic
applications in seizures and other neuropsychiatric and
neurodegenerative diseases. However, to explore such pos-
sibility, it is necessary to identify a renewable source for
these cells compatible with their preclinical exploitation.
An interesting possibility is generating these cells from in
vitro diﬀerentiation of embryonic or somatic neural stem
cells (ESCs and NSCs, resp.). NSCs can be isolated from
mouse and human neural tissues and can be propagated
for long time in cultures as neurospheres or in adhesive
conditions [97–100]. Upon diﬀerentiation, NSCs generate a
mixed population of GABAergic and glutamatergic neurons,
whose ratio is dependent on specific growth culture and
diﬀerentiation conditions [97, 101]. However, these cells
show generally poor developmental plasticity. In fact, after
prolonged time in culture, they retain only in part the
molecular regional code identity of the area from which
they originate and result generally resistant to be coaxed to
other neuronal subtypes [102–104]. In contrast, numerous
results have shown how ESCs can be converted eﬃciently in
various neuronal subtypes. In particular, some procedures
have been recently proposed for directing ESC diﬀerentiation
into cortical GABAergic interneurons. In an elegant set of
experiments, Danjo and colleagues refined the timing and
concentrations of Sonic Hedgehog (Shh) stimulation for
inducing ESCs neural ventralization and generating either
LGE or MGE progenitors [105]. In the latter case, ESC-
derivedMGE progenitors displayed the ability tomigrate and
distribute into the developing cortex generating GABAergic
interneurons. Interestingly, the authors further showed how
a diverse source of FGF signalling can alternatively select
for an MGE- or CGE-derived GABAergic cell fate. These
results set the experimental conditions to generate diﬀerent
subtypes of cortical GABAergic interneurons with specific
electrophysiological and connectivity properties. Further, a
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diﬀerent study showed the ability of ESC-derived MGE pro-
genitors to complete their maturation once transplanted in
vivo generating functional cells with physiological and neu-
rochemical characteristic of GABAergic cortical interneurons
[106]. These findings lay the ground for testing the potential
of ESC-derived GABAergic interneurons to treat preclinical
model of neurological disorders upon direct cell transplanta-
tion.
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